Sagility B.V. is reported to be preparing a stake sale in Sagility Limited, a healthcare operations provider, a move that would reduce the promoter's 50.95% holding if completed.
Moneycontrol reported, citing sources, that IIFL Capital had launched a block deal of up to $249.6 million, with Sagility B.V. expected to sell about 12% of Sagility at ₹42.45 per share. Livemint also reported the proposed sale and price. The terms have not been confirmed in company disclosures.
Sagility's shareholding filing showed Sagility B.V. held 50.95% as of Sept. 30, 2026. The filing also recorded an earlier sale of 769 million shares, equal to 16.427% of Sagility, in a transaction settled Nov. 17, 2025. That sale reduced the promoter's stake from 67.38% to 50.95%.
Sagility reported revenue of ₹20.321 billion ($212.6 million) for the quarter ended Sept. 30, up 22.5% year over year. Adjusted profit after tax rose 8.1% to ₹3.254 billion ($34 million), while reported profit after tax increased 13.3% to ₹2.842 billion.
Adjusted EBITDA increased 23% to ₹5.353 billion, with a margin of 26.3%. Group Chief Financial Officer Srinivas Mattapalli said the quarter delivered “our highest adjusted EBITDA margin in six quarters.” Sagility describes itself as a healthcare operations partner to U.S. payers, providers and pharmacy benefit managers.
The company said the second half of FY27 is seasonally stronger. Its board declared an interim dividend of ₹0.15 per share, with Oct. 30, 2026, as the record date and payment due on or before Nov. 21.
